Connection

John O'Bryan to Humans

This is a "connection" page, showing publications John O'Bryan has written about Humans.
Connection Strength

0.628
  1. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322.
    View in: PubMed
    Score: 0.030
  2. Targeting the "undruggable" RAS with biologics. Adv Cancer Res. 2022; 153:237-266.
    View in: PubMed
    Score: 0.029
  3. Targeting the KRAS a4-a5 allosteric interface inhibits pancreatic cancer tumorigenesis. Small GTPases. 2022 Jan; 13(1):114-127.
    View in: PubMed
    Score: 0.029
  4. Probing RAS Function with Monobodies. Methods Mol Biol. 2021; 2262:281-302.
    View in: PubMed
    Score: 0.028
  5. Inhibition of RAS: proven and potential vulnerabilities. Biochem Soc Trans. 2020 10 30; 48(5):1831-1841.
    View in: PubMed
    Score: 0.028
  6. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146.
    View in: PubMed
    Score: 0.027
  7. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570.
    View in: PubMed
    Score: 0.026
  8. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 2019 01; 139:503-511.
    View in: PubMed
    Score: 0.024
  9. Targeting the a4-a5 interface of RAS results in multiple levels of inhibition. Small GTPases. 2019 09; 10(5):378-387.
    View in: PubMed
    Score: 0.023
  10. Direct inhibition of RAS: Quest for the Holy Grail? Semin Cancer Biol. 2019 02; 54:138-148.
    View in: PubMed
    Score: 0.023
  11. Inhibition of RAS function through targeting an allosteric regulatory site. Nat Chem Biol. 2017 Jan; 13(1):62-68.
    View in: PubMed
    Score: 0.021
  12. Intersectin scaffold proteins and their role in cell signaling and endocytosis. Biochim Biophys Acta Mol Cell Res. 2017 Jan; 1864(1):23-30.
    View in: PubMed
    Score: 0.021
  13. Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2?) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett. 2015 Apr 10; 359(2):262-8.
    View in: PubMed
    Score: 0.019
  14. Receptor tyrosine kinase ubiquitylation involves the dynamic regulation of Cbl-Spry2 by intersectin 1 and the Shp2 tyrosine phosphatase. Mol Cell Biol. 2014 Jan; 34(2):271-9.
    View in: PubMed
    Score: 0.017
  15. Emerging roles for intersectin (ITSN) in regulating signaling and disease pathways. Int J Mol Sci. 2013 Apr 10; 14(4):7829-52.
    View in: PubMed
    Score: 0.016
  16. A new dimension to Ras function: a novel role for nucleotide-free Ras in Class II phosphatidylinositol 3-kinase beta (PI3KC2?) regulation. PLoS One. 2012; 7(9):e45360.
    View in: PubMed
    Score: 0.016
  17. Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. PLoS One. 2012; 7(4):e36023.
    View in: PubMed
    Score: 0.015
  18. Intersectin 1 is required for neuroblastoma tumorigenesis. Oncogene. 2012 Nov 15; 31(46):4828-34.
    View in: PubMed
    Score: 0.015
  19. Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction. Mol Cell Biol. 2012 Feb; 32(4):817-25.
    View in: PubMed
    Score: 0.015
  20. Intersectin 1 contributes to phenotypes in vivo: implications for Down's syndrome. Neuroreport. 2011 Oct 26; 22(15):767-72.
    View in: PubMed
    Score: 0.015
  21. Intersecting pathways in cell biology. Sci Signal. 2010 Dec 14; 3(152):re10.
    View in: PubMed
    Score: 0.014
  22. Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2beta-AKT pathway. Mol Cell Biol. 2007 Nov; 27(22):7906-17.
    View in: PubMed
    Score: 0.011
  23. Intersectin enhances huntingtin aggregation and neurodegeneration through activation of c-Jun-NH2-terminal kinase. Hum Mol Genet. 2007 Aug 01; 16(15):1862-71.
    View in: PubMed
    Score: 0.011
  24. Ubiquitin-interacting motifs inhibit aggregation of polyQ-expanded huntingtin. J Biol Chem. 2007 Mar 30; 282(13):10096-10103.
    View in: PubMed
    Score: 0.011
  25. Intersectin regulates epidermal growth factor receptor endocytosis, ubiquitylation, and signaling. Mol Pharmacol. 2006 Nov; 70(5):1643-53.
    View in: PubMed
    Score: 0.010
  26. The U-box ligase carboxyl-terminus of Hsc 70-interacting protein ubiquitylates Epsin. Biochem Biophys Res Commun. 2005 Mar 11; 328(2):550-9.
    View in: PubMed
    Score: 0.009
  27. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. J Biol Chem. 2004 Aug 06; 279(32):33528-37.
    View in: PubMed
    Score: 0.009
  28. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J Biol Chem. 2003 Nov 21; 278(47):47038-45.
    View in: PubMed
    Score: 0.008
  29. Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket. Proc Natl Acad Sci U S A. 2022 10 25; 119(43):e2204481119.
    View in: PubMed
    Score: 0.008
  30. Ceramide synthase 6 impacts T-cell allogeneic response and graft-versus-host disease through regulating N-RAS/ERK pathway. Leukemia. 2022 07; 36(7):1907-1915.
    View in: PubMed
    Score: 0.008
  31. Neuroblastoma differentiation in?vivo excludes cranial tumors. Dev Cell. 2021 10 11; 56(19):2752-2764.e6.
    View in: PubMed
    Score: 0.007
  32. Mitogenesis and endocytosis: What's at the INTERSECTIoN? Oncogene. 2001 Oct 01; 20(44):6300-8.
    View in: PubMed
    Score: 0.007
  33. The P-type ATPase transporter ATP7A promotes angiogenesis by limiting autophagic degradation of VEGFR2. Nat Commun. 2021 05 25; 12(1):3091.
    View in: PubMed
    Score: 0.007
  34. Selective and noncovalent targeting of RAS mutants for inhibition and degradation. Nat Commun. 2021 05 11; 12(1):2656.
    View in: PubMed
    Score: 0.007
  35. Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways. J Biol Chem. 2000 Sep 01; 275(35):27414-20.
    View in: PubMed
    Score: 0.007
  36. The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor. J Biol Chem. 1998 Aug 07; 273(32):20431-7.
    View in: PubMed
    Score: 0.006
  37. Akt2 (Protein Kinase B Beta) Stabilizes ATP7A, a Copper Transporter for Extracellular Superoxide Dismutase, in Vascular Smooth Muscle: Novel Mechanism to Limit Endothelial Dysfunction in Type 2 Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2018 03; 38(3):529-541.
    View in: PubMed
    Score: 0.006
  38. Silencing Intersectin 1 Slows Orthotopic Neuroblastoma Growth in Mice. J Pediatr Hematol Oncol. 2017 11; 39(8):e413-e418.
    View in: PubMed
    Score: 0.006
  39. Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC. J Biol Chem. 1996 May 17; 271(20):11787-91.
    View in: PubMed
    Score: 0.005
  40. A mammalian adaptor protein with conserved Src homology 2 and phosphotyrosine-binding domains is related to Shc and is specifically expressed in the brain. Proc Natl Acad Sci U S A. 1996 Apr 02; 93(7):2729-34.
    View in: PubMed
    Score: 0.005
  41. Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity. J Biol Chem. 2015 May 08; 290(19):12058-67.
    View in: PubMed
    Score: 0.005
  42. UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy. Cell Signal. 2015 May; 27(5):908-22.
    View in: PubMed
    Score: 0.005
  43. The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage. J Biol Chem. 1995 Jan 13; 270(2):551-7.
    View in: PubMed
    Score: 0.005
  44. Down syndrome: genes, model systems, and progress towards pharmacotherapies and clinical trials for cognitive deficits. Cytogenet Genome Res. 2013; 141(4):260-71.
    View in: PubMed
    Score: 0.004
  45. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991 Oct; 11(10):5016-31.
    View in: PubMed
    Score: 0.004
  46. The ubiquitin-interacting motif protein, S5a, is ubiquitinated by all types of ubiquitin ligases by a mechanism different from typical substrate recognition. J Biol Chem. 2009 May 08; 284(19):12622-32.
    View in: PubMed
    Score: 0.003
  47. The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res. 2004 Feb 15; 64(4):1266-77.
    View in: PubMed
    Score: 0.002
  48. Involvement of NH(2)-terminal sequences in the negative regulation of Vav signaling and transforming activity. J Biol Chem. 1999 Oct 22; 274(43):30410-8.
    View in: PubMed
    Score: 0.002
  49. Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood. 1994 Sep 15; 84(6):1931-41.
    View in: PubMed
    Score: 0.001
  50. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene. 1990 Sep; 5(9):1391-5.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.